KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $733.7 million.

  • Royalty Pharma's Capital Expenditures rose 4779.58% to $733.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.7 billion, marking a year-over-year decrease of 3224.53%. This contributed to the annual value of $1.7 billion for FY2025, which is 3224.53% down from last year.
  • According to the latest figures from Q4 2025, Royalty Pharma's Capital Expenditures is $733.7 million, which was up 4779.58% from $961.9 million recorded in Q3 2025.
  • Royalty Pharma's Capital Expenditures' 5-year high stood at $1.3 billion during Q3 2021, with a 5-year trough of $85000.0 in Q1 2022.
  • Its 5-year average for Capital Expenditures is $512.6 million, with a median of $473.8 million in 2023.
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 9998.31% in 2022, then surged by 70778823.53% in 2023.
  • Royalty Pharma's Capital Expenditures (Quarter) stood at $171.7 million in 2021, then soared by 45.71% to $250.2 million in 2022, then surged by 300.51% to $1.0 billion in 2023, then crashed by 50.47% to $496.4 million in 2024, then soared by 47.8% to $733.7 million in 2025.
  • Its last three reported values are $733.7 million in Q4 2025, $961.9 million for Q3 2025, and $1.1 million during Q2 2025.